Regulatory effects of osteoprotegerin on cellular and humoral immune responses.

Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · see citing works

Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.

Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · see citing works

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

Keane, J., Gershon, S. K., Wise, R. P., Mirabile‐Levens, E., Kasznica, J. M., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,683 · see citing works

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.

Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · see citing works

Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.

Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · see citing works

Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., & Martin, T. J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0367 · Cited by 2,317 · see citing works

A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.

Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290 · see citing works

RANK is essential for osteoclast and lymph node development.

Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478 · see citing works

Apoptosis control by death and decoy receptors

Ashkenazi, A., & Dixit, V. M. (1999) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(99)80034-9 · Cited by 1,281 · see citing works

Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL

Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S. D., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.23.14363 · Cited by 1,183 · see citing works

An Essential Role for BAFF in the Normal Development of B Cells Through a BCMA-Independent Pathway

Schiemann, B. J., Gommerman, J. L., Vora, K. A., Cachero, T. G., Shulga‐Morskaya, S., Dobles, M., Frew, E. M., & Scott, M. L. (2001) · Science · doi:10.1126/science.1061964 · Cited by 1,070 · see citing works

TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells

Wong, B. R., Rho, J., Arron, J. R., Robinson, E. A., Orlinick, J. R., Chao, M. V., Kalachikov, S. M., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042 · see citing works

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor.

Wong, B. R., Josien, R., Lee, S. Y., Sauter, B., Li, H.-L., Steinman, R. M., & Choi, Y. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.186.12.2075 · Cited by 853 · see citing works

T-cell co-stimulation through B7RP-1 and ICOS

Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U. M., Guo, J., Horan, T., Shih, G. C., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 772 · see citing works

Primer on the metabolic bone diseases and disorders of mineral metabolism.

Laurence, M. (2000) · Journal of Bone and Joint Surgery - British Volume · doi:10.1302/0301-620x.82b7.0821087b · Cited by 684 · see citing works

Modulation of Osteoclast Differentiation and Function by the New Members of the Tumor Necrosis Factor Receptor and Ligand Families

Suda, T. (1999) · Endocrine Reviews · doi:10.1210/er.20.3.345 · Cited by 485 · see citing works

The effect of a single dose of osteoprotegerin in postmenopausal women.

Bekker, P. J., Holloway, D., Nakanishi, A., Arrighi, M., Leese, P. T., & Dunstan, C. R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.348 · Cited by 484 · see citing works

Journal of Bone and Mineral Research

Delmas, P. D. (1993) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650081323 · Cited by 454 · see citing works

APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity

Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M. J., Ramakrishnan, M., McCabe, S., Qiu, W., Kornuc, M., Xia, X.-Z., et al. (2000) · Nature Immunology · doi:10.1038/79802 · Cited by 362 · see citing works

TRANCE, a TNF Family Member, Is Differentially Expressed on T Cell Subsets and Induces Cytokine Production in Dendritic Cells

Josien, R., Wong, B. R., Li, H., Steinman, R. M., & Choi, Y. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.5.2562 · Cited by 317 · see citing works

OPG/FDCR-1, a TNF receptor family member, is expressed in lymphoid cells and is up-regulated by ligating CD40.

Yun, T. J., Chaudhary, P. M., Shu, G. L., Frazer, J. K., Ewings, M. K., Schwartz, S. M., Pascual, V., Hood, L. E., & Clark3, E. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.11.6113 · Cited by 307 · see citing works

Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.

Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 289 · see citing works

TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation.

Bachmann, M. F., Wong, B. R., Josien, R., Steinman, R. M., Oxenius, A., & Choi, Y. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.7.1025 · Cited by 260 · see citing works

Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function.

Yun, T. J., Tallquist, M. D., Aicher, A., Rafferty, K. L., Marshall, A. J., Moon, J. J., Ewings, M. K., Mohaupt, M., Herring, S. W., & Clark, E. A. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1482 · Cited by 195 · see citing works

A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1β, TNF-α, PTH, PTHrP, and 1,25(OH)2D3.

Morony, S., Capparelli, C., Lee, R., Shimamoto, G., Boone, T., Lacey, D. L., & Dunstan, C. R. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.9.1478 · Cited by 187 · see citing works

Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.

Capparelli, C., Kostenuik, P. J., Morony, S., Starnes, C. O., Weimann, B., Van, G. Y., Scully, S. A., Qi, M., Lacey, D. L., & Dunstan, C. R. (2000) · PubMed · Cited by 147 · see citing works

OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats.

Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., & Dunstan, C. R. (2001) · Endocrinology · doi:10.1210/endo.142.10.8437 · Cited by 140 · see citing works

Characterization of osteoclast precursors in human blood

Shalhoub, V., Elliott, G., Chiu, L., Manoukian, R., Kelley, M., Hawkins, N., Davy, E., Shimamoto, G. T., Beck, J., Kaufman, S., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02379.x · Cited by 130 · see citing works

Expression of tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors and sensitivity to TRAIL-induced apoptosis in primary B-cell acute lymphoblastic leukaemia cells

Clodi, K., Wimmer, D., Li, Y., Goodwin, R. G., Jaeger, U., Mann, G., Gadner, H., & Younes, A. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02404.x · Cited by 75 · see citing works

Regulatory Effects of Novel Neurotrophin-1/B Cell-Stimulating Factor-3 (Cardiotrophin-Like Cytokine) on B Cell Function

Senaldi, G., Stolina, M., Guo, J., Faggioni, R., McCabe, S., Kaufman, S. A., Van, G. Y., Xu, W., Fletcher, F. A., Boone, T. C., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.11.5690 · Cited by 54 · see citing works

Stimulatory Effects of B7-Related Protein-1 on Cellular and Humoral Immune Responses in Mice

Guo, J., Stolina, M., BREADY, J. V., Yin, S., Horan, T., Yoshinaga, S. K., & Senaldi, G. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.9.5578 · Cited by 47 · see citing works

To B or not to B: TNF family signaling in lymphocytes

Siegel, R. M., & Lenardo, M. J. (2001) · Nature Immunology · doi:10.1038/89715 · Cited by 29 · see citing works

Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease

Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824 · see citing works

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

Lacey, D. L., Boyle, W. J., Simonet, W. S., Kostenuik, P. J., Dougall, W. C., Sullivan, J. K., Martín, J. S., & Dansey, R. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3705 · Cited by 692 · see citing works

Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women

Bone, H. G., Bolognese, M. A., Yuen, C. K., Kendler, D. L., Wang, H., Liu, Y., & Martín, J. S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2814 · Cited by 421 · see citing works

Osteoprotegerin Inactivation Accelerates Advanced Atherosclerotic Lesion Progression and Calcification in Older ApoE ^−/− Mice

Bennett, B. J., Scatena, M., Kirk, E. A., Rattazzi, M., Varon, R. M., Averill, M., Schwartz, S. M., Giachelli, C. M., & Rosenfeld, M. E. (2006) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000236428.91125.e6 · Cited by 304 · see citing works

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

Ferrari, S., & Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1326-y · Cited by 157 · see citing works

Clinical development of anti-RANKL therapy

Schwarz, E. M., & Ritchlin, C. T. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2171 · Cited by 138 · see citing works

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

Watts, N. B., Roux, C., Modlin, J. F., Brown, J. P., Daniels, A., Jackson, S. M., Smith, S. Y., Zack, D. J., Zhou, L., Grauer, A., et al. (2011) · Osteoporosis International · doi:10.1007/s00198-011-1755-2 · Cited by 134 · see citing works

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

Dempster, D. W., Lambing, C. L., Kostenuik, P. J., & Grauer, A. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.02.002 · Cited by 134 · see citing works

The anti-tumor effect of RANKL inhibition in malignant solid tumors – A systematic review

de Groot, A. F., Appelman‐Dijkstra, N. M., van der Burg, S. H., & Kroep, J. R. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.10.010 · Cited by 127 · see citing works

RANK ligand as a therapeutic target for bone metastases and multiple myeloma

Roodman, G. D., & Dougall, W. C. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.09.002 · Cited by 127 · see citing works

Osteoprotegerin (OPG)—a potential new role in the regulation of endothelialcell phenotype and tumour angiogenesis?

Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K. L., Neville-Webbe, H. L., Down, J. M., Reed, M., Coleman, R. E., et al. (2005) · International Journal of Cancer · doi:10.1002/ijc.21606 · Cited by 108 · see citing works

HMGB1 is a bone‐active cytokine

Yang, J., Shah, R., Robling, A. G., Templeton, E., Yang, H., Tracey, K. J., & Bidwell, J. P. (2008) · Journal of Cellular Physiology · doi:10.1002/jcp.21268 · Cited by 97 · see citing works

Syndecan-1 Is Involved in Osteoprotegerin-Induced Chemotaxis in Human Peripheral Blood Monocytes

Mosheimer, B. A., Kaneider, N. C., Feistritzer, C., Djanani, A. M., Sturn, D. H., Patsch, J. R., & Wiedermann, C. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1895 · Cited by 89 · see citing works

Effects of RANKL-Targeted Therapy in Immunity and Cancer

Cheng, M. L., & Fong, L. H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00329 · Cited by 87 · see citing works

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications

Body, J. J., Bergmann, P., Boonen, S., Devogelaer, J.-P., Gielen, E., Goemaere, S., Kaufman, J., Rozenberg, S., & Reginster, J.-Y. (2012) · Osteoporosis International · doi:10.1007/s00198-011-1891-8 · Cited by 83 · see citing works

Erosive arthritis

Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2166 · Cited by 73 · see citing works

A review of denosumab for the treatment of osteoporosis

Miyazaki, T., Tokimura, F., & Tanaka, S. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s46192 · Cited by 67 · see citing works

Osteoprotegerin Is Associated With Aneurysm Diameter and Proteolysis in Abdominal Aortic Aneurysm Disease

Koole, D., Hurks, R., Schoneveld, A. H., Vink, A., Golledge, J., Moran, C. S., de Kleijn, D. P. V., van Herwaarden, J. A., de Vries, J. P. P. M., Laman, J. D., et al. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.243592 · Cited by 63 · see citing works

Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss

Titanji, K. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01851 · Cited by 61 · see citing works

Denosumab for the treatment of bone metastases in breast cancer: evidence and opinion

Steger, G. G., & Bartsch, R. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011412656 · Cited by 53 · see citing works

Receptor activator of nuclear factor kappa B ligand antagonists inhibit tissue inflammation and bone loss in experimental periodontitis

Yuan, H., Gupte, R. K., Zelkha, S., & Amar, S. (2011) · Journal Of Clinical Periodontology · doi:10.1111/j.1600-051x.2011.01780.x · Cited by 52 · see citing works

Receptor Activator of NF-κB Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection

Miller, R. E., Branstetter, D. G., Armstrong, A. P., Kennedy, B., Jones, J. C., Cowan, L. A., Bussiere, J. L., & Dougall, W. C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.1.266 · Cited by 46 · see citing works

Influence of RANKL inhibition on immune system in the treatment of bone diseases

Fouque-Aubert, A., & Chapurlat, R. D. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.05.004 · Cited by 44 · see citing works

The development of denosumab for the treatment of diseases of bone loss and cancer‐induced bone destruction

Goessl, C. D., Katz, L., Dougall, W. C., Kostenuik, P. J., Zoog, H. B., Braun, A., Dansey, R., & Wagman, R. B. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06674.x · Cited by 40 · see citing works

RANKL inhibition for the management of patients with benign metabolic bone disorders

Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 37 · see citing works

Osteoprotegerin Deficiency Limits Angiotensin II–Induced Aortic Dilatation and Rupture in the Apolipoprotein E–Knockout Mouse

Moran, C. S., Jose, R. J., Biroš, E., & Golledge, J. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.304587 · Cited by 36 · see citing works

Osteoporosis in Systemic Lupus Erythematosus Mechanisms

Lee, C., & Ramsey‐Goldman, R. (2005) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2005.01.004 · Cited by 35 · see citing works

Effects of antiresorptive agents on osteomyelitis

Li, D., Gromov, K., Proulx, S. T., Xie, C. L., Li, J., Crane, D. P., Søballé, K., O’Keefe, R. J., Awad, H. A., Xing, L., et al. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05210.x · Cited by 33 · see citing works

RANKL-targeted therapy inhibits bone resorption in experimental Staphylococcus aureus-induced arthritis

Verdrengh, M., Bokarewa, M. I., Ohlsson, C., Stolina, M., & Tarkowski, A. (2009) · Bone · doi:10.1016/j.bone.2009.10.028 · Cited by 32 · see citing works

Denosumab for the treatment of bone metastases in advanced breast cancer

Casas, A., Llombart‐Cussac, A., & Martín, M. (2013) · The Breast · doi:10.1016/j.breast.2013.05.007 · Cited by 32 · see citing works

RANKL Inhibition: From Mice to Men (and Women)

Stolina, M., Kostenuik, P. J., Dougall, W. C., Fitzpatrick, L. A., & Zack, D. J. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-72009-8_18 · Cited by 30 · see citing works

Role of denosumab in breast cancer

Bartsch, R., & Steger, G. G. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903146877 · Cited by 8 · see citing works

Effects of RANKL inhibition on inflammation and immunity

Ferrari‐Lacraz, S., & Ferrari, S. (2009) · IBMS BoneKEy · doi:10.1138/20090369 · Cited by 6 · see citing works

Genetic deletion of osteoprotegerin attenuates asthma development through suppression of inflammatory response in mice

Miyake, T., Miyake, T., & Morishita, R. (2022) · Cellular Immunology · doi:10.1016/j.cellimm.2022.104559 · Cited by 4 · see citing works

Breast Cancer: Rank Ligand Inhibition

Bartsch, R., Steger, G. G., Gnant, M., & Ziebermayr, R. (2010) · Breast Care · doi:10.1159/000321122 · Cited by 4 · see citing works

OSTEOPOROSIS IN CHRONIC LIVER DISEASE: PATHOGENESIS, DIAGNOSTICS, AND TREATMENT

Мялюк, О. П., Марущак, М. І., Баб’як, О. В., Sabadyshyn, R. O., & Палапа, В. В. (2023) · doi:10.32782/2226-2008-2023-3-15 · Cited by 1 · see citing works

Osteoprotegerin (OPG) and its ligands RANKL and TRAIL in falciparum, vivax and knowlesi malaria: correlations with disease severity, and B cell production of OPGPreprint

Nair, A. S., Woodford, J., Loughland, J. R., Andrew, D. W., Piera, K. A., Amante, F. H., William, T., Grigg, M. J., McCarthy, J. S., Anstey, N. M., et al. (2024) · medRxiv · doi:10.1101/2024.07.22.24310838 · Cited by 1 · see citing works

Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel

Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21

Doença óssea em pacientes com nefrite lúpica: aspectos inflamatórios

Resende, A. L. (2014) · doi:10.11606/t.5.2014.tde-15082014-142821

Denosumab: A Novel Agent for Osteoporosis

Horning, K. K., Hegge, K. A., & Bottenberg, M. M. (2009) · Journal of Pharmacy Technology · doi:10.1177/875512250902500205

Influence d’une inhibition de RANKL sur le système immunitaire dans le traitement des maladies osseuses

Fouque-Aubert, A., & Chapurlat, R. D. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.05.018

OSTEOCLASTOGENESIS AND LYMPH NODE ORGANOGENESIS IN DIFFERENT SPECIES OF EGYPTIAN RATS

Saad, A.-H., & Abdel‐Gaber, R. (2013) · Journal of the Egyptian Society of Parasitology · doi:10.12816/0006367

CHAPTER 18 RANKL INHIBITION: FROM MICE TO MEN (AND WOMEN)

Stolina, M., Kostenuik, P. J., Dougall, W. C., & Zack, D. J. (2007)

Osteoprotegerin and its ligands RANKL and TRAIL in falciparum, vivax, and knowlesi malaria

Nair, A. S., Woodford, J., Loughland, J. R., Andrew, D. W., Piera, K. A., Amante, F. H., William, T., Grigg, M. J., McCarthy, J. S., Anstey, N. M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.112768

Immune Function of the Decoy Receptor Osteoprotegerin

Ryan, E. J., & Bengtsson, Å. K. (2002) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.v22.i3.30 · Cited by 37 · see citing works

Continuous RANKL Inhibition in Osteoprotegerin Transgenic Mice and Rats Suppresses Bone Resorption without Impairing Lymphorganogenesis or Functional Immune Responses

Stolina, M., Dwyer, D., Ominsky, M. S., Corbin, T., Van, G., Bolon, B., Sarosi, I., McCabe, J., Zack, D. J., & Kostenuik, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.11.7497 · Cited by 63 · see citing works

Osteoprotegerin ligand: a regulator of immune responses and bone physiology

Kong, Y., Boyle, W. J., & Penninger, J. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01718-7 · Cited by 160 · see citing works

Role for osteoprotegerin in rheumatoid inflammation

Saidenberg-Kermanac’h, N., Cohen-Solal, M. E., Bessis, N., de Vernejoul, M. C., & Boissier, M. (2004) · Joint Bone Spine · doi:10.1016/s1297-319x(03)00131-3 · Cited by 93 · see citing works

Beyond bone remodeling–emerging functions of osteoprotegerin in host defense and microbial infection

Kobayashi‐Sakamoto, M., Tamai, R., & Kiyoura, Y. (2015) · Integrative Molecular Medicine · doi:10.15761/imm.1000173 · Cited by 9 · see citing works